The FDA Is Running on Generic Email Addresses. What Does That Mean for Your Regulatory Team?

When the FDA loses capacity to manage its operations, the compliance burden doesn't disappear. It relocates, onto the regulatory affairs and quality teams inside the companies it regulates.

If you're in medical device manufacturing, you know that shift is already underway. Your teams are making more decisions without FDA input, navigating longer timelines with less guidance, and doing it in an environment that is harder to work in than it was two years ago.

The mechanism was straightforward, if not tidy. In February 2025, roughly 700 FDA employees were let go. In April, another 3,500 followed - nearly 20% of the agency's entire workforce, with more than 220 cuts coming from the medical device center alone.

Some of those employees received termination emails stating they were not fit for continued employment. Days later, different emails arrived from the FDA's Office of Talent Solutions, notifying them their terminations had been rescinded effective immediately and thanking them for their service. Their managers weren’t told any of it was happening.

For employees, the experience was disorienting at best. For the industry they regulate, the consequences are still playing out.

Organizations that survive and grow in this era will know where that workforce burden is showing up before it becomes a quality problem.

How did staffing cuts impact FDA capacity?

The device-focused cuts hit the Center for Devices and Radiological Health hard, including specialists in AI, digital health, and emerging medical technologies.

The effects on review capacity became measurable fast:

• De Novo classification decisions dropped roughly 50% in the first half of 2025 compared to the same period in 2024.

• Original PMA approvals fell from 12 to 8 over the same window.

• The Q-Sub program, which allows device companies to get early feedback before submitting, was cut back. Meetings were converted to written responses only.

• Key FDA databases tracking drug approvals, labeling changes, and manufacturing information went without updates for extended periods.

One current FDA official described the situation: things that used to function are no longer functioning.

When the agency loses the institutional knowledge needed to run its own operations, the burden of navigating ambiguity shifts to the companies it regulates.

Who's left holding the compliance burden?

The regulation your teams work under doesn't pause because the regulator is understaffed. Submission timelines still exist. MDUFA goals are still on the books. Inspections still happen, if less predictably.

What changes is the environment:

• Less pre-submission guidance means more decisions made without FDA input, at higher risk of a deficiency letter or rejection.

• Slower review timelines mean longer periods of uncertainty for products in the pipeline.

• The institutional knowledge experienced FDA reviewers carried, the informal sense of what the agency will and won't accept, is being rebuilt from scratch on both sides.

Your regulatory professionals are good at their jobs. They're also being asked to do those jobs in conditions that have become more challenging to work under.

What sustained uncertainty does to performance

There's a difference between a hard problem and an ambiguous one. Hard problems have defined parameters. Your team knows what they're solving for, even when the solution is difficult.

Ambiguous problems, where the rules are unclear and the feedback loop has broken down, are cognitively expensive in a different way. They require constant reassessment and sustained tolerance for not knowing.

meQ's research on change readiness shows that most employees are not equipped by default to operate well in that kind of environment. Without specific skills, people under prolonged uncertainty tend to feel more reactive, more fatigued, and less effective at the precise judgment work regulatory affairs requires.

The same research shows that these skills are trainable. Employees who develop them are:

• 72% more likely to see the practical opportunities in a changing environment.
• 50% more likely to engage constructively rather than resist.
• 60% less likely to be derailed by disruptive announcements.

How does HR help prepare the workforce for regulatory challenges?

The regulatory affairs function is not where HR spends a lot of time. But the conditions that determine how well your regulatory team performs are exactly what workforce resilience programs are built to address.

Three things are worth acting on now:

• Find out what your regulatory and quality teams are facing. Not a formal survey, but real conversation. The FDA disruption has been ongoing for over a year, and if you haven’t asked your teams how they're navigating it, they probably haven't told you.
• Don't treat this as an individual problem. The conditions are structural. The answer is building the specific capabilities, ambiguity tolerance, and focused judgment under pressure that let people do precision work in imprecise conditions.
• Watch for downstream effects on quality. A regulatory team that is overloaded and under-supported makes more errors. In this industry, errors have serious consequences.

How meQ helped a Fortune 100 firm in a high-regulation environment 

The FDA situation is a visible version of something that appears across regulated industries: compliance demands increase, the workforce isn't resourced to match, and the result is errors, delays, or quiet degradation in quality.

meQ helped a Fortune 100 firm under intense regulatory scrutiny in exactly this way. A targeted intervention identified where the gap was building and addressed it before it became a quality control problem, resulting in a 14% improvement in productivity and a 23% improvement in quality of life for their people.

The FDA will eventually stabilize. The question is what shape your regulatory workforce will be in when it does.

Are you supporting your workforce through change?

meQ's predictive analytics platform gives HR and quality leaders real-time visibility into workforce conditions before they become performance or compliance problems. If you work in medical device manufacturing and want to understand what your data could be telling you, book a demo with our team.

Sources

Associated Press / Fortune. FDA scrambles to rehire entire teams overseeing medical devices after DOGE cuts. February 24, 2025.

Definitive Healthcare. FDA Job Cuts Impact on the Life Sciences Industry. 2025.

ProPharma Group. Navigating a Shifting Regulatory Landscape: The Impact of FDA Layoffs on Medical Device Developers. June 26, 2025.

Axios. Key FDA drug data goes missing amid DOGE cuts. April 24, 2025.

MDDI Online. Factors Influencing FDA Clearance Time for Medical Devices. October 2025.

Emergo by UL. FDA CDRH Announces Priorities for Fiscal Year 2026. 2025.

meQ. Leading Through Volatility: What CHROs Need to Do Right Now. 2024.

meQ. Customer Case Studies. February 2026.